SillaJen Unveils Clinical Results for Anticancer Drug BAL0891 at ESMO, "Signs of Efficacy Observed"
Predicted impact: Medium
Clinical efficacy signals for a drug candidate at a major oncology congress; small company.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.